TpP measures blood levels of soluble fibrin, which is the immediate precursor to a key component of blood clots. TpP offers physicians the right information at the right time, and allows them to make the best possible treatment decision. It is estimated that the worldwide market for the TpP test is 350 million tests annually. This exceeds the number of American women who die each year of breast cancer.
PE is now the most frequent cause of death associated with childbirth.
Early detection of life threatening conditions such as acute MI provides physicians with an important window of opportunity during which life-saving drugs can be administered.